[144] CorMedix Inc. SEC Filing

Rhea-AI Filing Summary

CorMedix Inc. (CRMD) has filed a Form 144 reporting a proposed sale of 300,000 common shares through Merrill Lynch on 09/03/2025 on the NASDAQ, with an aggregate market value of $4,350,000.00. The filing shows the shares were acquired and are to be paid for on 09/03/2025 under a Stock Plan Activity from the issuer. The company reports 74,648,992 shares outstanding, so the proposed sale represents approximately 0.40% of outstanding common stock. The filer indicates there were no shares sold by the same person in the past three months and includes the standard certification that no material nonpublic information is known by the seller.

Insights

Securities Analyst

TL;DR: Routine insider/planned sale under a stock plan: 300,000 shares (~0.40%) to be sold via Merrill Lynch for $4.35M.

The Form 144 documents a single proposed disposition of 300,000 common shares acquired under a stock plan and to be sold on 09/03/2025 through Merrill Lynch on NASDAQ. The filing supplies concrete figures for shares outstanding and aggregate market value, and notes no related sales in the prior three months. For analysts, this is a transparent, single-event disclosure rather than a multi-month selling program; its size (≈0.40% of outstanding) is modest relative to the total float, suggesting limited immediate market impact from supply alone.

Corporate Governance Expert

TL;DR: Compliance-focused filing that documents a stock-plan transfer and planned sale, including the standard no-material-nonpublic-information attestation.

The notice indicates the securities were issued under a stock plan and are being sold the same day as acquisition, with the filer affirming the absence of undisclosed material information. The inclusion of broker, timing, and acquisition/payment dates follows Rule 144 disclosure requirements and signals procedural compliance. There is no information in the filing about the identity of the seller beyond the rule definition, nor about any trading plan adoption date.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 1800 K ST NW Suite 800 Washington DC 20006	300000	4350000.00	74648992	09/03/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/03/2025	Stock Plan Activity	Issuer			300000	09/03/2025	n/a

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for CRMD report?

The form reports a proposed sale of 300,000 common shares via Merrill Lynch on 09/03/2025 with an aggregate market value of $4,350,000.

How many CorMedix (CRMD) shares are outstanding per the filing?

The filing lists 74,648,992 shares outstanding.

How was the 300,000 CRMD shares acquired according to the filing?

The shares were acquired on 09/03/2025 under a Stock Plan Activity from the issuer and paid for on the same date.

Did the filer sell any CRMD shares in the past three months?

The filing states Nothing to Report for securities sold during the past three months by the same person.

Which broker and exchange are involved in the proposed sale?

The broker is listed as Merrill Lynch, 1800 K St NW Suite 800 Washington DC 20006 and the sale is to occur on NASDAQ.